The Characteristics of TCM Clinical Trials: A Systematic Review of ClinicalTrials.gov
Table 3
Trial location and sponsor of TCM interventional studies.
Parameter
Number/total number (%)
All Trials
Oct 2000–Sep 2005
Oct 2005–Sep 2010
Oct 2010–Sep 2015
Region, N
Africa
8/1270 (0.6)
1/95 (1.1)
1/396 (0.3)
6/779 (0.8)
Asia-Pacific
670/1270 (52.8)
28/95 (29.5)
185/396 (46.7)
457/779 (58.7)
Central and South America
52/1270 (4.1)
5/95 (5.3)
24/396 (6.1)
23/779 (3.0)
Europe
195/1270 (15.4)
19/95 (20.0)
81/396 (20.5)
95/779 (12.2)
Middle East
28/1270 (2.2)
0
10/396 (2.5)
18/779 (2.3)
North America
362/1270 (28.5)
78/95 (82.1)
140/396 (35.4)
144/779 (18.5)
Lead sponsor, N
Industry
63/1270 (5.0)
5/95 (5.3)
13/396 (3.3)
45/779 (5.8)
NIH
55/1270 (4.3)
46/95 (48.4)
7/396 (1.8)
2/779 (0.3)
US Fed (non-NIH)
28/1270 (2.2)
1/95 (1.1)
12/396 (3.0)
15/779 (1.9)
Other
1124/1270 (88.5)
43/95 (45.3)
364/396 (91.9)
717/779 (92.0)
Country of lead ponsor , N
China
527/1270 (41.5)
14/95 (14.7)
142/396 (35.9)
371/779 (47.6)
United States
360/1270 (28.3)
76/95 (80.0)
140/396 (35.4)
144/779 (18.5)
Korea
58/1270 (4.6)
1/95 (1.1)
13/396 (3.3)
44/779 (5.6)
Germany
42/1270 (3.3)
1/95 (1.1)
19/396 (4.8)
22/779 (2.8)
Canada
39/1270 (3.1)
3/95 (3.2)
17/396 (4.3)
19/779 (2.4)
Brazil
35/1270 (2.8)
2/95 (2.1)
10/396 (2.5)
23/779 (3.0)
Israel
20/1270 (1.6)
0
8/396 (2.0)
12/779 (1.5)
Spain
17/1270 (1.3)
1/95 (1.1)
3/396 (0.8)
13/779 (1.7)
United Kingdom
16/1270 (1.3)
2/95 (2.1)
7/396 (1.8)
7/779 (0.9)
Sweden
15/1270 (1.2)
0
8/396 (2.0)
7/779 (0.9)
For the TCM trials, further manual classification of the “other” lead sponsor group found that this group was all composed of academic institutions/medical centers. Only listing the top 10 countries of lead sponsor. Including Taiwan and Hong Kong.
